Uke 14: Molekylær MRD ved AML

Uke 14: Molekylær MRD ved AML

BACKGROUND

Patients with acute myeloid leukemia (AML) often reach complete remission, but relapse rates remain high. Next-generation sequencing enables the detection of molecular minimal residual disease in virtually every patient, but its clinical value for the prediction of relapse has yet to be established.

Molecular Minimal Residual Disease  in Acute Myeloid Leukemia - NEJM